Anti-inflammatory activity of curcumin-loaded tetrahedral framework nucleic acids on acute gouty arthritis.
Gouty arthritis
Macrophage
NF-κB signaling pathway
Oxidative stress
Tetrahedral framework DNA nanoparticle
Journal
Bioactive materials
ISSN: 2452-199X
Titre abrégé: Bioact Mater
Pays: China
ID NLM: 101685294
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
11
03
2021
revised:
25
05
2021
accepted:
03
06
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Gouty arthritis is a very familiar inflammatory arthritis. Controlling inflammation is the key to preventing gouty arthritis. However, colchicine, the most highly represented drug used in clinical practice, has strict contraindications owing to some severe side effects. Curcumin (Cur), a natural anti-inflammatory drug, has demonstrated good safety and efficacy. However, the rapid degradation, poor aqueous solubility, and low bioavailability of Cur limit its therapeutic effect. To strengthen the effectiveness and bioavailability of Cur. Cur loaded tetrahedral framework nucleic acids (Cur-TFNAs) were synthesized to deliver Cur. Compared with free Cur, Cur-TFNAs exhibit a preferable drug stability, good biocompatibility (CCK-8 assay), ease of uptake (immunofluorescence), and higher tissue utilization (in vivo biodistribution). Most importantly, Cur-TFNAs present better anti-inflammatory effect than free Cur both in vivo and in vitro experiments through the determination of inflammation-related cytokines expression. Therefore, we believe that Cur-TFNAs have great prospects for the prevention of gout and similar inflammatory diseases.
Identifiants
pubmed: 34541407
doi: 10.1016/j.bioactmat.2021.06.003
pii: S2452-199X(21)00286-3
pmc: PMC8429917
doi:
Types de publication
Journal Article
Langues
eng
Pagination
368-380Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
There is no conflict to declare.
Références
Nat Protoc. 2015 Oct;10(10):1508-24
pubmed: 26357007
Arthritis Rheum. 1991 Jul;34(7):894-903
pubmed: 2059236
Life Sci. 2004 Jun 25;75(6):639-53
pubmed: 15172174
Ann Rheum Dis. 2012 Feb;71(2):180-5
pubmed: 21917822
Nanomedicine. 2019 Oct;21:102061
pubmed: 31344499
Nat Commun. 2018 Jun 29;9(1):2550
pubmed: 29959312
Chem Rev. 2019 May 22;119(10):6459-6506
pubmed: 29465222
Nat Prod Rep. 2011 Nov;28(12):1937-55
pubmed: 21979811
ACS Appl Mater Interfaces. 2019 Feb 20;11(7):6850-6857
pubmed: 30698411
FASEB J. 1992 Sep;6(12):3051-64
pubmed: 1381691
ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39525-39533
pubmed: 31601097
Nat Immunol. 2001 Oct;2(10):907-16
pubmed: 11577346
Bioact Mater. 2021 Jan 23;6(8):2281-2290
pubmed: 33553815
ACS Appl Mater Interfaces. 2019 Aug 28;11(34):30631-30639
pubmed: 31382735
Acc Chem Res. 2015 Jul 21;48(7):2075-83
pubmed: 26158541
Nanomedicine. 2015 Jan;11(1):195-206
pubmed: 25240595
Clin Cancer Res. 2008 Oct 1;14(19):6228-36
pubmed: 18829502
Cell Death Dis. 2017 Oct 5;8(10):e3074
pubmed: 28981106
Arthritis Rheumatol. 2019 Jun;71(6):991-999
pubmed: 30618180
Nat Rev Dis Primers. 2019 Sep 26;5(1):69
pubmed: 31558729
Biomaterials. 2010 Sep;31(25):6597-611
pubmed: 20553984
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Nat Rev Rheumatol. 2014 May;10(5):271-83
pubmed: 24614592
Sci Signal. 2008 Jan 08;1(1):pe1
pubmed: 18270169
Life Sci. 2006 Mar 27;78(18):2081-7
pubmed: 16413584
Small. 2018 Aug;14(32):e1800703
pubmed: 30009516
J Control Release. 2002 Jul 18;82(1):105-14
pubmed: 12106981
Circulation. 1999 Nov 9;100(19 Suppl):II361-4
pubmed: 10567330
Biomaterials. 2008 Apr;29(12):1912-9
pubmed: 18242692
J Neuroinflammation. 2011 Sep 29;8:125
pubmed: 21958395
Genes Dev. 1995 Nov 15;9(22):2736-46
pubmed: 7590249
Nanomedicine (Lond). 2010 Apr;5(3):433-49
pubmed: 20394536
Trends Immunol. 2015 Mar;36(3):161-78
pubmed: 25687683
J Intern Med. 2003 Jun;253(6):643-52
pubmed: 12755960
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Biomaterials. 2015;53:475-83
pubmed: 25890744
Molecules. 2011 Jun 03;16(6):4567-98
pubmed: 21642934
Annu Rev Med. 2012;63:185-98
pubmed: 21888516
Biomaterials. 2012 Feb;33(5):1238-44
pubmed: 22078811
Brain Res. 2009 Jul 28;1282:133-41
pubmed: 19445907
Drug Saf. 1994 Oct;11(4):252-8
pubmed: 7848545
Nano Lett. 2020 May 13;20(5):3602-3610
pubmed: 32272018
Cell. 2007 Sep 7;130(5):765-8
pubmed: 17803897
J Clin Rheumatol. 2013 Jan;19(1):19-29
pubmed: 23319019
ACS Nano. 2014 Jan 28;8(1):76-103
pubmed: 24467380
Nat Protoc. 2020 Aug;15(8):2728-2757
pubmed: 32669637
Nano Lett. 2018 Sep 12;18(9):5652-5659
pubmed: 30088771
Biomacromolecules. 2008 Nov;9(11):3039-43
pubmed: 18821795
Lancet. 2016 Oct 22;388(10055):2039-2052
pubmed: 27112094
Nanomedicine (Lond). 2009 Jul;4(5):519-30
pubmed: 19572818
Nanoscale. 2018 Mar 28;10(12):5457-5465
pubmed: 29484330
Clin Cancer Res. 2005 May 1;11(9):3567-73
pubmed: 15867261
ACS Nano. 2014 Feb 25;8(2):1213-21
pubmed: 24386907
Am Fam Physician. 2014 Dec 15;90(12):831-6
pubmed: 25591183
Adv Mater. 2013 Aug 27;25(32):4386-96
pubmed: 23765613
Autoimmun Rev. 2009 Jun;8(7):627-31
pubmed: 19232550
Arthritis Rheum. 2009 Jan;60(1):281-9
pubmed: 19116939
ACS Nano. 2011 Jul 26;5(7):5427-32
pubmed: 21696187
Postepy Hig Med Dosw (Online). 2012 Apr 16;66:187-95
pubmed: 22706103
Bone Res. 2020 Feb 10;8:6
pubmed: 32047705
J Control Release. 2006 Aug 10;114(1):100-9
pubmed: 16831482